zur Navigation zum Inhalt
Onkologie 9. April 2012

Therapy of AL amyloidosis – work-up and treatment at our centre

Systemic light-chain amyloidosis (AL amyloidosis) is a rare protein folding disorder in which monoclonal light chains are deposited as insoluble fibrillar aggregates. The most common cause of the disease is a monoclonal plasma cell disorder. Currently, the only clinically relevant treatment option is chemotherapy, targeting the underlying neoplastic cells. Patients are often in a poor general state of health with organ functions being impaired by amyloid deposits. In recent years, several new treatment protocols have been introduced, which give clinicians a variety of options to adapt treatment to the patients' needs. For this reason a thorough assessment must be performed so that each patient receives the best individual treatment option.

Zu diesem Thema wurden noch keine Kommentare abgegeben.

Mehr zum Thema

<< Seite 1 >>

Medizin heute

Aktuelle Printausgaben